![]() |
市場調查報告書
商品編碼
1880532
實驗室耗材市場預測至2032年:按產品類型、材料類型、分銷管道、應用、最終用戶和地區分類的全球分析Lab Supplies Market Forecasts to 2032 - Global Analysis By Product Type (Equipment, Consumables, and Other Product Types), Material Type, Distribution Channel, Application, End User and By Geography |
||||||
根據 Stratistics MRC 預測,全球實驗室耗材市場規模預計在 2025 年達到 500.2 億美元,並在 2032 年達到 944.2 億美元,預測期內複合年成長率 (CAGR) 為 9.5%。實驗室耗材涵蓋科學、醫療和工業實驗室活動所需的基本材料、耗材和設備,包括玻璃器皿、塑膠耗材、化學品、移液器、防護設備以及樣品製備和檢測工具。這些耗材對於確保結果準確、維持流程一致性以及創造安全的工作環境至關重要。它們支持學術界、臨床界和商界開展的各種實驗室活動,包括研究、診斷檢測、實驗和品質保證等。
根據 Peterson-KFF 醫療系統追蹤器發表的報導,2020 年美國醫療費用支出成長了 9.7%,達到 4.1 兆美元,這一增幅遠高於 2019 年的 4.3%。
增加研發投入
科研活動的激增推動了對高品質實驗室耗材、分析儀器和先進樣品處理工具的需求。自動化、人工智慧驅動的工作流程系統和高通量篩檢平台等技術進步進一步推動了對現代化實驗室耗材的需求。學術機構和合約研究組織(CRO)正在擴大其研究範圍,從而增加了採購量。基因組學、藥物研發和分子診斷領域的投資不斷成長,促使實驗室採用更精確、可重複且數位化整合的儀器。隨著全球科學研究生態系統的日益成熟,實驗室耗材製造商正在加速創新,以支持新的科學應用。
熟練人員短缺
許多機構難以操作先進設備,例如自動化分析儀、定序平台和基於人工智慧的實驗室資訊系統。人才短缺導致各機構和研究中心更加依賴大規模的培訓項目,從而增加了營運成本。尤其是小規模的實驗室,由於缺乏具備必要專業知識的人員,在整合升級設備方面面臨許多挑戰。此外,監管合規和品質保證方面的複雜性也給人員不足的實驗室帶來了更大的負擔。
自動化和人工智慧/物聯網整合
自動化液體處理系統、智慧離心機和雲端基礎的庫存管理平台正在提高精度並減少人為錯誤。物聯網監控工具正在幫助改善資產追蹤、耗材使用預測和品管。人工智慧演算法正在支援預測性維護和即時工作流程最佳化。這些技術使實驗室能夠擴大產能、更快地提供檢測結果並提高結果的可重複性。隨著自動化技術的普及,供應商正在為研發、臨床診斷和工業實驗室開發客製化、模組化且易於使用的解決方案。
激烈的價格競爭
微量吸管尖、試管和試劑等耗材的商品化導致價格競爭加劇,利潤率不斷下降。低成本供應商(尤其是來自新興市場的供應商)的崛起正在重塑採購格局。為了保持競爭力,主要企業正投資於精益生產、自動化生產和數位化分銷平台。對價格敏感的客戶傾向於大量採購、可重複使用產品和具成本效益產品,這迫使企業實現產品線多元化。
全球供應鏈的嚴重中斷迫使實驗室緊急重新思考其籌資策略並加強庫存韌性。此次危機加速了自動化樣本處理、遠距離診斷和雲端基礎的實驗室管理解決方案的普及。緊急監管途徑加快了診斷材料和偵測設備的核准。疫情過後,實驗室繼續優先考慮準備工作、自動化和分散式檢查模式。這種轉變永久增加了對高品質、擴充性且數位化整合的實驗室耗材的需求。
預計在預測期內,設備細分市場將佔據最大的市場佔有率。
由於設備在支援廣泛的研究、診斷和分析活動中發揮至關重要的作用,預計在預測期內,設備領域將佔據最大的市場佔有率。光強度、培養箱、離心機和生物安全櫃等先進設備的日益普及,鞏固了該領域的主導地位。觸控螢幕介面、物聯網監控和節能設計等持續的技術創新,正在提升設備的運作效能。生物製藥研發和分子生物學研究的拓展,推動了對精密儀器的需求。實驗室也在對其舊有系統進行升級改造,以整合自動化和智慧連接功能。
預計在預測期內,臨床和診斷檢查室領域將呈現最高的複合年成長率。
預計在預測期內,臨床和診斷檢查室領域將實現最高成長率,這主要得益於檢測量的成長、感染疾病監測範圍的擴大以及預防保健意識的提高。分子診斷、免疫檢測和照護現場平台技術的進步正在推動高性能檢測耗材的普及。這些檢查室越來越依賴自動化分析儀、快速檢測套組和數據驅動的工作流程系統來提高效率。數位化實驗室資訊管理系統(LIMS)平台和基於人工智慧的診斷工具能夠加快檢體追蹤和臨床決策速度。分散式檢查中心的擴張和私人診斷連鎖機構的發展正在推動耗材和設備的採購。
亞太地區預計將在預測期內佔據最大的市場佔有率,這主要得益於醫療基礎設施、生物醫學研究和診斷能力的快速發展。中國、印度、日本和韓國等國家正大力投資檢查室現代化以及設備和耗材的本土化生產。政府對生物技術、精準醫療和藥物研發的投入也推動了對先進檢測用品的需求。此外,該地區自動化、人工智慧驅動的分析和基於機器人的研究平台也得到了更廣泛的應用。全球製造商與區域企業之間的合作正在促進技術轉移並降低成本。
在預測期內,北美預計將展現出最高的複合年成長率,這主要得益於強勁的技術創新和對科學研究的大量投入。該地區在基因組學、蛋白質組學、細胞療法和人工智慧驅動的實驗室操作等領域處於領先地位。實驗室正在迅速採用數位化工作流程系統、智慧儀器和先進的自動化技術來提高生產力。完善的法規結構和資金籌措計劃正在促進新型實驗室技術的快速商業化。頂尖大學、生物製藥公司和臨床研究機構正在推動高品質實驗室耗材的持續高需求。
According to Stratistics MRC, the Global Lab Supplies Market is accounted for $50.02 billion in 2025 and is expected to reach $94.42 billion by 2032 growing at a CAGR of 9.5% during the forecast period. Laboratory supplies encompass the fundamental materials, consumables, and instruments required for conducting scientific, medical, and industrial lab activities. They include items such as glassware, plastic consumables, chemicals, pipettes, protective equipment, and tools used for sample preparation and testing. These supplies are vital for ensuring accurate results, consistent processes, and safe working conditions. They support a wide range of laboratory functions, including research, diagnostic testing, experimentation, and quality-assurance tasks in academic, clinical, and commercial settings.
According to an article published by the PETERSON-KFF Health System Tracker, healthcare spending in the U.S. increased by 9.7% and reached USD 4.1 trillion in 2020, significantly faster than the 4.3% increase in 2019.
Increasing R&D investment
The surge in research activity is intensifying the need for high-quality lab consumables, analytical instruments, and advanced sample-processing tools. Technological advancements such as automation, AI-enabled workflow systems, and high-throughput screening platforms are further boosting demand for modern lab supplies. Academic institutes and CROs are expanding their research scope, encouraging higher procurement volumes. Growing investment in genomics, drug discovery, and molecular diagnostics is pushing laboratories to adopt more precise, reproducible, and digitally integrated equipment. As global research ecosystems mature, lab supply manufacturers are accelerating innovation to support emerging scientific applications.
Shortage of skilled personnel
Many facilities struggle with operating sophisticated instruments such as automated analyzers, sequencing platforms, and AI-based laboratory information systems. This talent gap increases dependency on extensive training programs, raising operational costs for institutions and research centers. Small laboratories, in particular, face challenges integrating upgraded equipment due to limited staffing expertise. The complexity of regulatory compliance and quality assurance adds further burden to understaffed labs.
Integration of automation and AI/IoT
Automated liquid handling systems, smart centrifuges, and cloud-based inventory platforms are enabling greater accuracy and reducing manual errors. IoT-enabled monitoring tools are improving asset tracking, consumable usage prediction, and quality control. AI algorithms are now supporting predictive maintenance and real-time workflow optimization. These technologies are allowing laboratories to scale capacity, accelerate testing turnaround times, and enhance reproducibility. As automation becomes more accessible, suppliers are developing modular, user-friendly solutions tailored for research, clinical diagnostics, and industrial laboratories.
Intense price competition
The commoditization of consumables such as pipette tips, tubes, and reagents has led to competitive pricing strategies and shrinking margins. Increased presence of low-cost suppliers, especially from emerging markets, is reshaping procurement dynamics. To stay competitive, key players are investing in lean manufacturing, automation-driven production, and digital distribution platforms. Price-sensitive customers are opting for bulk procurement, reusable items, and value-tier products, pushing companies to diversify their offerings.
Global supply chains faced severe disruptions, prompting laboratories to reassess sourcing strategies and strengthen inventory resilience. The crisis also stimulated rapid adoption of automated sample handling, remote diagnostics, and cloud-based lab management solutions. Emergency regulatory pathways facilitated quicker approval of diagnostic materials and testing equipment. Post-pandemic, laboratories continue to prioritize preparedness, automation, and decentralized testing models. This shift has permanently amplified demand for high-quality, scalable, and digitally integrated lab supplies.
The equipment segment is expected to be the largest during the forecast period
The equipment segment is expected to account for the largest market share during the forecast period, due to its essential role in supporting a wide range of research, diagnostic, and analytical activities. High adoption of advanced instruments such as spectrophotometers, incubators, centrifuges, and biosafety cabinets is strengthening this segment's leadership. Continuous technological advancements, including touchscreen interfaces, IoT-enabled monitoring, and energy-efficient designs, are improving operational performance. The expansion of biopharma R&D and molecular biology studies is driving demand for precision equipment. Laboratories are also upgrading legacy systems to integrate automation and smart connectivity.
The clinical & diagnostic laboratories segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the clinical & diagnostic laboratories segment is predicted to witness the highest growth rate, due to rising testing volumes, expanding infectious disease surveillance, and increased preventive healthcare awareness. Advancements in molecular diagnostics, immunoassays, and point-of-care platforms are boosting the adoption of high-performance lab supplies. These labs increasingly rely on automated analyzers, rapid test kits, and data-driven workflow systems to improve efficiency. Digital LIMS platforms and AI-based diagnostic tools are enabling faster sample tracking and quicker clinical decisions. The expansion of decentralized testing centers and private diagnostic chains is fueling procurement of consumables and equipment.
During the forecast period, the Asia Pacific region is expected to hold the largest market share, driven by rapid expansion of healthcare infrastructure, biomedical research, and diagnostic capacity. Countries such as China, India, Japan, and South Korea are investing heavily in laboratory modernization and local production of equipment and consumables. Government funding for biotechnology, precision medicine, and pharmaceutical R&D is accelerating demand for advanced lab supplies. The region is also experiencing rising adoption of automation, AI-driven analytics, and robotics-based research platforms. Collaborative partnerships between global manufacturers and regional players are enhancing technology transfer and affordability.
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to strong technological innovation and substantial investment in scientific research. The region leads advancements in genomics, proteomics, cell therapy, and AI-driven laboratory operations. Laboratories are rapidly integrating digital workflow systems, smart instruments, and advanced automation to enhance productivity. Supportive regulatory frameworks and funding programs are encouraging faster commercialization of new lab technologies. Major universities, biopharma companies, and clinical research organizations consistently drive high consumption of premium lab supplies.
Key players in the market
Some of the key players in Lab Supplies Market include Thermo Fisher Scientific, QIAGEN N.V., Danaher Corporation, Shimadzu Corporation, Merck KGaA, Mettler-Toledo, Agilent Technologies, Waters Corporation, Sartorius AG, Bruker Corporation, Avantor Inc., PerkinElmer, Corning Incorporated, Bio-Rad Laboratories, and Eppendorf.
In October 2025, Thermo Fisher Scientific Inc. announced a definitive agreement to acquire Clario Holdings, Inc., a leading provider of endpoint data solutions for clinical trials, from a shareholder group led by Astorg and Nordic Capital, Novo Holdings and Cinven, for $8.875 billion in cash at close plus potential additional earnout and other payments in the future, largely dependent on performance.
In October 2025, Merck has entered into a partnership with Promega Corporation, a global life science solutions and service leader based in Madison, Wisconsin in the US, to co-develop novel technologies that advance drug screening and discovery. The agreement unites Merck's strength in organoids and synthetic chemistry with Promega's market leading assay and reporter technologies.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.